A Brain tumor occurs when there is an abnormal proliferation of cells, know as Neoplasm, in the brain. A brain tumor can be benign or malignant (cancerous), and they are not invariably fatal. However, all brain tumors are life -threatening, as they invade the limited space of the intracranial cavity. Symptoms of brain tumor include headache, vomiting, somnolence, hypertensions. There can also be cognitive impairment. The patient may face memory loss, impaired taste and aural senses, visual problems. They may also be attacked with epileptic seizures and abnormal fatigue.

We have very effective treatment protocol for brain tumors/brain cancer. This treatment form is being used in more than 80 countries.

Different types of Brain Tumor/Cancer


A tumor that arises from the glial cells in brain or spine is known as glioma. A Glioma can be benign or malignant. Symptoms include headache, nausea, vomiting and seizure. Cranial nerve disorder can also happen.


A highly malignant brain tumor that occurs in the cerebellum is known as meduloblastoma. Symptoms include morning headache, dizziness, facial sensory loss, motor weakness and repeated vomiting.


Meningioma is also a common brain tumor that arises within the meninges. These tumors are generally benign, but they can often be malignant. Focal seizure, spastic weakness in legs and increased intracranial pressure are symptoms of Meningioma.

Recently we conducted a Kaplan-Meier survival analysis of our cases of glioma brain tumors, comparing those who were treated exclusively by the Banerji Protocol with those who also had other conventional Western medical treatment either before or during our treatment. For the 91 cases treated exclusively with the Ruta /Calc Phos protocol, mean survival time was 92 months. For the 11 cases treated with conventional plus Banerji therapy, mean survival time was 20 months.
Among those who were on the Banerji Protocol without any other treatment, 7% of the cases were completely cured with our therapy. 60% were improved, 22% achieved status quo, and 11% were worse or expired. Mean follow-up time was 23 months.